Advertisement

FBIO

Fortress Biotech, Inc.

Healthcare · USD

Set alert

Price alert · FBIO

All alert types
1.92 USD -0.08 -4.00%
As of Oct 30, 2026 Extended hours 1.92 0.00%
Bid
1.92 × 1
Ask
1.93 × 1
1.89 Day range 2.01
1.87 52-week range 4.38
YTD
-47.54%
1 year
-25.29%
Open
2.01
Prev close
2.00
Mkt cap
64.03M
Vol
196.84K
Avg vol
410.92K
EPS
2.76
P/E
0.70
Div yield
0.00%
More statistics
Low
1.89
High
2.01
Forward P/E
-0.99
Beta
1.75
Short ratio
4.57
Inst. own
15.78%
Dividend
0.00
Ex-div date
50-d avg
1.83
200-d avg
1.84
1y target
14.33

5D chart

Chart tools
Interval
FBIO five-day price chart1.851.911.962.012.07Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
48.03M
Enterprise value
12.37M
Trailing P/E
0.00
Forward P/E
-0.99
PEG ratio
0.00
Price / sales
0.58
Price / book
1.17
EPS (TTM)
-2.96
Beta
1.75
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-49.25%
Revenue (TTM)
82.62M
Revenue growth
-14.30%
Free cash flow
-59.20M
Total cash
76.20M
Total debt
88.42M
Return on equity
0.00%
Shares outstanding
27.60M
Short % of float
11.50%
50-day average
1.83
200-day average
1.84

Analyst view

Consensus: none

Price target (mean) 14.33 +646.5% upside
Target (low)
4.00
Target (mean)
14.33
Target (high)
24.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.75.

Earnings history

Financials — quick view

All financials
FBIO Revenue — quarterly 18.72M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
FBIO Net income — quarterly -468.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
FBIO EPS — quarterly -0.08
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

FBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.27-0.76-0.49-181.48%
Aug 13, 2024Jun 1, 2024-1.32-0.73+0.59+44.70%
May 15, 2024Mar 1, 2024-2.03-1.03+1.00+49.26%
Mar 28, 2024Dec 1, 20230.00-0.53——
Nov 14, 2023Sep 1, 2023-3.53-0.94+2.59+73.37%
Aug 14, 2023Jun 1, 2023-3.90-3.60+0.30+7.69%

Upgrades / downgrades

FBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 18, 2024HC Wainwright & Co.mainBuyBuy
Jul 19, 2024HC Wainwright & Co.reitBuyBuy
Jun 20, 2024Cantor Fitzgeraldreit—Overweight
May 16, 2024Roth MKMreitBuyBuy
Mar 19, 2024Alliance Global Partnersinit—Buy
Nov 29, 2023Roth MKMmainBuyBuy

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on FBIO — it syncs with the Stock Master app.

Insider holders

FBIO insider holders
InsiderRelationLatest transactionDateShares held
HARVEY JIMMIEDirectorStock Award(Grant)Dec 28, 202369,999
HOENLEIN MALCOLMDirectorStock Award(Grant)Dec 28, 202339,042
JIN DAVIDChief Financial OfficerStock Award(Grant)Sep 30, 2024240,893
KLEIN DOVDirectorSaleMay 19, 202453,400
LOBELL JONAH JAYDirectorStock Award(Grant)Dec 28, 2023115,692
LORENZ KEVIN R.DirectorStock Award(Grant)Dec 28, 202324,970

Institution ownership

FBIO institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.26%625,0541.09MSep 29, 2024
Cambridge Investment Research Advisors Inc.2.01%554,400964.66KSep 29, 2024
Rosalind Advisors, Inc.1.82%502,828874.92KSep 29, 2024
Acadian Asset Management. LLC1.75%482,595839.72KSep 29, 2024
Shikiar Asset Management, Inc.0.85%235,969410.59KSep 29, 2024
Envestnet Asset Management0.67%183,946320.07KSep 29, 2024

Fund ownership

FBIO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.70%470,544818.75KSep 29, 2024
Vanguard Extended Market Index Fund0.55%152,474265.30KSep 29, 2024
Fidelity Extended Market Index Fund0.35%95,862166.80KOct 30, 2024
iShares Micro Cap ETF0.12%33,08657.57KOct 30, 2024
Fidelity Total Market Index Fund0.11%29,29750.98KOct 30, 2024
Fidelity Series Total Market Index Fund0.08%22,65539.42KOct 30, 2024
Advertisement